Impact of integrase inhibitors on cardiovascular disease events in people with HIV starting antiretroviral therapy
Background
Integrase strand transfer inhibitors (INSTIs) have been associated with an increased risk for cardiovascular disease (CVD) events. We investigated the impact of starting INSTI-based antiretroviral therapy (ART) on CVD events among treatment-naïve people with human immunodeficiency virus using a target trial framework, which reduces the potential for confounding and selection bias.
Methods
We included Swiss HIV Cohort Study participants who were ART-naïve after May 2008, when INSTIs became available in Switzerland. Individuals were categorized according to their first ART regimen (INSTI vs other ART) and were followed from ART start until the first of CVD event (myocardial infarction, stroke, or invasive cardiovascular procedure), loss to follow-up, death, or last cohort visit. We calculated hazard ratios and risk differences using pooled logistic regression models with inverse probability of treatment and censoring weights.
Results
Of 5362 participants (median age 38 years, 21% women, 15% of African origin), 1837 (34.3%) started INSTI-based ART, and 3525 (65.7%) started other ART. Within 4.9 years (interquartile range, 2.4–7.4), 116 CVD events occurred. Starting INSTI-based ART was not associated with an increased risk for CVD events (adjusted hazard ratio, 0.80; 95% confidence interval [CI], .46–1.39). Adjusted risk differences between individuals who started INSTIs and those who started other ART were −0.17% (95% CI, −.37 to .19) after 1 year, −0.61% (−1.54 to 0.22) after 5 years, and −0.71% (−2.16 to 0.94) after 8 years.
Conclusions
In this target trial emulation, we found no difference in short- or long-term risk for CVD events between treatment-naïve people with human immunodeficiency virus who started INSTI-based ART and those on other ART.
Топ-30
Журналы
|
1
2
3
4
|
|
|
The Lancet HIV
4 публикации, 10.53%
|
|
|
HIV Medicine
3 публикации, 7.89%
|
|
|
AIDS Research and Human Retroviruses
3 публикации, 7.89%
|
|
|
Circulation Research
3 публикации, 7.89%
|
|
|
Journal of Antimicrobial Chemotherapy
3 публикации, 7.89%
|
|
|
Clinical Infectious Diseases
2 публикации, 5.26%
|
|
|
Frontiers in Medicine
1 публикация, 2.63%
|
|
|
Current Opinion in HIV and AIDS
1 публикация, 2.63%
|
|
|
Clinical Microbiology Reviews
1 публикация, 2.63%
|
|
|
Viruses
1 публикация, 2.63%
|
|
|
JAMA network open
1 публикация, 2.63%
|
|
|
Expert Review of Clinical Pharmacology
1 публикация, 2.63%
|
|
|
AIDS
1 публикация, 2.63%
|
|
|
Infectious Disease Clinics of North America
1 публикация, 2.63%
|
|
|
Open Forum Infectious Diseases
1 публикация, 2.63%
|
|
|
Current Infectious Disease Reports
1 публикация, 2.63%
|
|
|
JAMA - Journal of the American Medical Association
1 публикация, 2.63%
|
|
|
HIV Research and Clinical Practice
1 публикация, 2.63%
|
|
|
Journal of Vascular Diseases
1 публикация, 2.63%
|
|
|
Current Problems in Cardiology
1 публикация, 2.63%
|
|
|
Journal of primary care & community health
1 публикация, 2.63%
|
|
|
Journal of Infectious Diseases
1 публикация, 2.63%
|
|
|
Antiviral Research
1 публикация, 2.63%
|
|
|
Internal Medicine Journal
1 публикация, 2.63%
|
|
|
EClinicalMedicine
1 публикация, 2.63%
|
|
|
Annals of Epidemiology
1 публикация, 2.63%
|
|
|
1
2
3
4
|
Издатели
|
1
2
3
4
5
6
7
8
9
|
|
|
Elsevier
9 публикаций, 23.68%
|
|
|
Oxford University Press
7 публикаций, 18.42%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
5 публикаций, 13.16%
|
|
|
Wiley
4 публикации, 10.53%
|
|
|
Mary Ann Liebert
3 публикации, 7.89%
|
|
|
MDPI
2 публикации, 5.26%
|
|
|
American Medical Association (AMA)
2 публикации, 5.26%
|
|
|
Taylor & Francis
2 публикации, 5.26%
|
|
|
Frontiers Media S.A.
1 публикация, 2.63%
|
|
|
American Society for Microbiology
1 публикация, 2.63%
|
|
|
Springer Nature
1 публикация, 2.63%
|
|
|
SAGE
1 публикация, 2.63%
|
|
|
1
2
3
4
5
6
7
8
9
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.